H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on Pluristem (PSTI) today and set a price target of $3.50. The company’s shares closed on Friday at $0.85, close to its 52-week low of $0.80.
Ramakanth observed:
“We maintain our Buy rating of Pluristem and our 12-month price target of $3.50 per share. We derived our price target based on the average of two valuation methods: 1) price-sales multiple analysis applying a 6x multiple to our 2026 sales estimate discounted at 14%; and 2) price-earnings multiple analysis applying a 21x multiple to our 2026 estimated earnings discounted at 14%. (1) clinical; (2) commercial; (3) partnership; (4) financial; and (5) intellectual property.”
According to TipRanks.com, Ramakanth is a 1-star analyst with an average return of -1.4% and a 33.8% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals Inc, IntelGenx Technologies, and Tyme Technologies Inc.
Currently, the analyst consensus on Pluristem is a Moderate Buy with an average price target of $3.25, implying a 282.4% upside from current levels. In a report issued on December 4, Maxim Group also assigned a Buy rating to the stock with a $3 price target.
.
See today’s analyst top recommended stocks >>
Based on Pluristem’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $8.79 million. In comparison, last year the company had a GAAP net loss of $7.39 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Pluristem Therapeutics, Inc. is a biotechnology company, which engages in the provision of cell therapy development. It develops placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions.
